This is a correction article to a study on the use of thromboelastogram (TEG) and coagulation functions to assess blood clotting status in pregnant women at different trimesters.[1][2] The study examines changes in hemostasis during physiological pregnancy, when there is increased coagulation potential, decreased anticoagulant potential, and decreased fibrinolysis, creating an antithrombotic state.[1] The concentration of coagulation factors VII, VIII, IX, X, XII, fibrinogen and von Willebrand factor is significantly increased throughout pregnancy.[1] Prothrombin and V factors remain unchanged, while factor XIII is elevated in early gestation and declines to 50% before delivery.[1] The thromboelastogram measures the viscoelastic properties of blood and parameters such as reaction time (R), K parameter, alpha angle, and maximum amplitude (MA) that reflect the initiation phase, propagation phase, and clotting force.[2] TEG helps assess coagulation in pregnant women across trimesters and can detect changes in clot strength caused by platelet-fibrinogen interaction.[2][1] Increased coagulation activation contributes to thrombin generation and the risk of thrombotic lesions in the placental circulation.[1]